Beranda › Dermatitis Atopik (Eksim) › Oregon
Uji klinis Dermatitis Atopik (Eksim) di Oregon
6 studi untuk Dermatitis Atopik (Eksim) mencari peserta di lokasi di Oregon.
Kota di Oregon
Teks studi resmi (Bahasa Inggris)
A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
- Investigational Site, Portland
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT07003425A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
- Inmagene Site 3, Portland
Menerima pesertaFase 2
Usia 18 hingga 74 · Semua jenis kelamin · Diperbarui 12 Agu 2026 · NCT07037901A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
- Oregon Health and Science University /ID# 266483, Portland
Menerima pesertaFase 3
Usia 2 hingga 11 · Semua jenis kelamin · Diperbarui 6 Agu 2026 · NCT06461897A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
- Leo Pharma Investigational site, Portland
Menerima pesertaFase 3
6 Months – 11 Years · Semua jenis kelamin · Diperbarui 7 Jul 2026 · NCT06311682A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
- Oregon Health and Science University /ID# 263736, Portland
Menerima pesertaFase 3
Usia 18 hingga 63 · Semua jenis kelamin · Diperbarui 6 Jul 2026 · NCT06389136Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
- Galderma Investigational Site 7073, Gresham
Menerima pesertaStudi observasional
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 13 Mar 2026 · NCT06988605Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.